| 신경과 영역에서의 디지털 치료의 현황과 향후 전망 |
| 김희진1, 김경민2, 김병수3, 김승우2, 백경원4, 석진명5, 선우준상6, 송인욱7, 우호걸8, 이익성9, 정진만10, 최교민11, 최윤호7, 양광익5, 대한신경과학회 진료지침위원회 |
1한양대학교 의과대학 신경과학교실
2연세대학교 의과대학 신경과학교실
3이화여자대학교 의과대학 이대목동병원 신경과
4고려대학교 안암병원 신경과
5순천향대학교 의과대학 순천향대학교 천안병원 신경과
6강북삼성병원 신경과
7가톨릭대학교 의과대학 인천성모병원 신경과
8경희대학교 의과대학 경희대학교병원 신경과
9중앙병원 신경과
10고려대학교 의과대학 고려대학교 안산병원 신경과
11건국대학교병원 신경과 |
| Latest Trends in Digital Therapeutics for Neurology |
| Hee-Jin Kim MD, PhD1, Kyung Min Kim MD, PhD2, Byung-Su Kim MD, PhD3, Seung Woo Kim MD, PhD2, Kyoungwon Baik MD, PhD4, Jin Myoung Seok MD, PhD5, Jun-Sang Sunwoo MD, PhD6, In-Uk Song MD, PhD7, Ho Geol Woo MD, PhD8, Eek-Sung Lee MD, PhD9, Jin-Man Jung MD, PhD10, Kyomin Choi MD, PhD11, Yun Ho Choi MD, PhD7, Kwang Ik Yang MD, PhD5, on behalf of the Clinical Practice Guideline Committee of Korean Neurological Association |
1Department of Neurology, College of Medicine, Hanyang University, Seoul, Korea
2Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
3Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea
4Department of Neurology, Korea University Anam Hospital, Seoul, Korea
5Department of Neurology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea
6Department of Neurology, Kangbuk Samsung Hospital, Seoul, Korea
7Department of Neurology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
8Department of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea
9Department of Neurology, Jungang Hospital, Jeju, Korea
10Department of Neurology, Korea University Ansan Hospital, Korea Universty College of Medicine, Ansan, Korea
11Department of Neurology, Konkuk University Medical Center, Seoul, Korea |
Corresponding Author:
Hee-Jin Kim ,Tel: +82-2-2220-8374, Fax: +82-2-2220-8374, Email: hyumcbrain@hanyang.ac.kr
|
|
Received: June 23, 2025 Revised: June 29, 2025 Accepted: July 3, 2025 Published online: August 1, 2025 |
|
|
| Abstract |
|
As societies age rapidly, the long-term medical and economic burdens of major neurological diseases -such as Alzheimer’s disease, Parkinson’s disease, and stroke- are increasing. Digital therapeutics (DTx), defined as evidence-based therapeutic interventions delivered via software for disease prevention, management, or treatment, are emerging as a novel paradigm in neurology. Unlike general health apps, DTx are developed for medical purposes and require clinical validation and regulatory approval. As of 2025, over 500 DTx products have been approved globally, including in the United States, China, Germany, and Belgium. DTx can be classified by purpose (e.g., prevention, treatment, adherence support), relationship to conventional care (standalone or adjunctive), and delivery modality (e.g., mobile apps, tablets, video games). In neurology, DTx are increasingly applied to remote cognitive training, symptom monitoring, and motor rehabilitation. Recent studies from 2023 to 2025 show growing evidence for their clinical effectiveness and usability in neurodegenerative and cerebrovascular diseases. This review outlines the current status of DTx in neurology with a focus on recent clinical trials, regulatory trends, and product platforms. Future directions include multimodal integrations, expanded reimbursement, regulatory streamlining, and personalized digital interventions. DTx offer significant potential to transform neurological care in an aging population. |
| Key Words:
Digital therapeutics | Dementia | Stroke | Parkinson disease | Rehabilitation |
|
PDF Links
Full text via DOI
Download Citation
